Overview
Medicare Advantage plans, also known as Medicare Part C, are private health insurance alternatives to traditional Medicare. These plans receive government payments to provide coverage to seniors and individuals with disabilities. Because they operate under government contracts, they are subject to oversight by the Department of Justice (DOJ) under the False Claims Act. When the DOJ suspects fraud—such as submitting false diagnoses to inflate payments—it may initiate a civil investigation or lawsuit. A critical aspect of such cases is gathering testimony from key executives who oversaw the plans. The recent dispute between the DOJ and Elevance Health (formerly Anthem) illustrates the high-stakes legal battles that can arise when a company resists providing access to top officials. This guide walks through the process step by step, using the Elevance case as a real-world example.
Prerequisites
Before diving into the steps, ensure you have a basic understanding of these concepts:
- Medicare Advantage (MA): A type of Medicare health plan offered by private insurance companies that contract with Medicare.
- False Claims Act (FCA): A U.S. federal law that imposes liability on persons or companies who defraud the government.
- Deposition: A sworn, out-of-court testimony given by a witness, often used to gather evidence for a lawsuit.
- Executive Witness: A company officer (e.g., CEO, head of Medicare plans) who may have personal knowledge of alleged fraudulent practices.
- DOJ Civil Division: The branch of the DOJ that handles fraud cases against companies.
No coding experience is needed, but familiarity with legal terminology will help.
Step-by-Step Instructions
Step 1: The DOJ Initiates a Fraud Investigation
The process often begins when the DOJ receives a whistleblower complaint or internal audit reveals suspicious billing patterns. In Elevance's case, the DOJ filed a lawsuit in 2020 alleging that the company submitted inaccurate diagnosis codes for Medicare Advantage enrollees to increase risk-adjusted payments. The investigation typically includes reviewing thousands of medical records, claims data, and internal emails.
Step 2: Identifying Key Witnesses and Executives
The DOJ identifies individuals who can speak to the company's policies and practices. For Elevance, that key witness was Peter Haytaian, the outgoing executive who oversaw Medicare Advantage operations. Executives like him are valuable because they can explain corporate intent, training, and oversight. The DOJ's attorneys send a formal request to depose these individuals.
Step 3: Requesting a Deposition
Once a witness is identified, the DOJ issues a deposition notice or request. This document specifies the time, place, and scope of questioning. In Elevance's situation, the DOJ first asked to depose Haytaian in early 2024. The timing is critical: shortly after that request, Elevance announced Haytaian's departure from the company, which the DOJ argued was an attempt to shield him from testimony.
Step 4: The Company's Response: Blocking or Negotiating Access
Companies may resist depositions for various reasons: executive unavailability, privilege claims, or strategic delay. Elevance blocked the deposition outright, refusing to make Haytaian available. The DOJ then escalated the issue by filing a letter with the presiding judge, detailing the obstruction. This letter is a formal legal document that lays out the facts and requests court intervention.
Step 5: Legal Maneuvering: Letters to the Judge and Court Orders
The DOJ's letter to the judge (made public in April 2025) argued that Elevance's timing of Haytaian's departure was suspicious. The letter highlighted the company's refusal to produce the executive, despite his direct involvement in the plans under scrutiny. The judge can then issue an order compelling the deposition or impose sanctions. This step often involves back-and-forth motions and hearings, prolonging the case.
Step 6: Impact on the Case and Broader Implications
The outcome of this dispute affects the entire lawsuit. If the DOJ gains access to Haytaian, his testimony could strengthen their case. If not, the government may seek adverse inferences (the jury can assume the testimony would have been harmful to Elevance). Beyond this case, the standoff underscores the high stakes: Elevance generated over $40 billion in revenue from Medicare Advantage plans in 2024, and a successful fraud suit could result in massive penalties. The dispute also highlights the broader regulatory scrutiny these plans face.
Common Mistakes
- Underestimating DOJ's persistence: The government has extensive resources and will pursue key witnesses. Attempting to block access can backfire lead to sanctions or negative publicity.
- Poor timing of executive departures: Announcing an executive’s exit immediately after a deposition request raises red flags. Courts may view this as obstruction.
- Inadequate documentation of internal policies: If a company does not have clear records of executive roles and responsibilities, it becomes harder to argue that the executive is not essential.
- Ignoring privilege issues upfront: Companies must carefully preserve attorney-client privilege but cannot use it as a blanket excuse to avoid all depositions.
Summary
Medicare Advantage fraud investigations require careful navigation of legal procedures, especially when deposing high-level executives. The DOJ vs. Elevance Health case demonstrates how a company's attempt to block access to a key witness can delay but not necessarily derail the case. By understanding the steps—from investigation initiation to court intervention—stakeholders can better anticipate challenges and avoid common pitfalls. The outcome of such disputes can have significant financial and reputational consequences for insurers.